Text message workouts could ease strain on hearts of PAH patients
NCT ID NCT06477640
First seen Jun 26, 2026 · Last updated Jul 16, 2026 · Updated 2 times
Summary
This study tests whether a home rehabilitation program using daily text or email messages with simple exercises can reduce the number of heartbeats needed during a 6-minute walk in people with pulmonary arterial hypertension (PAH). Researchers will enroll 55 adults with PAH and compare those who get exercise messages to those who get neutral messages. The goal is to see if this low-cost approach can improve heart efficiency and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- daily exercise messages via text or email
- What this could lead to
- If it works, this could offer a simple, low-cost way to help people with PAH manage their condition at home and feel better day-to-day.
- What could go wrong
- This is a small, early-stage study with only 55 participants, so results may not apply to everyone. The exercise program is gentle and low-risk, but it may not provide clear benefits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION (PAH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Rochester Medical Center
Rochester, New York, 14642, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an inhaled therapy replace a daily pill for PAH?
- Can a Real-World registry improve how treprostinil is used for PAH?
- Which PAH treatment strategy works better: adding a third drug or increasing the dose?
- Lung patients may soon do rehab from home via app
- Which drug is best for pulmonary hypertensive crisis? new trial aims to find out
- New PAH drug IKT-001 moves to Long-Term safety check